Assessing the Power of Exome Chips.

Genotyping chips for rare and low-frequent variants have recently gained popularity with the introduction of exome chips, but the utility of these chips remains unclear. These chips were designed using exome sequencing data from mainly American-European individuals, enriched for a narrow set of comm...

Full description

Bibliographic Details
Main Authors: Christian Magnus Page, Sergio E Baranzini, Bjørn-Helge Mevik, Steffan Daniel Bos, Hanne F Harbo, Bettina Kulle Andreassen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4593624?pdf=render
id doaj-866bd0af6eb94b89ba771bba630fed73
record_format Article
spelling doaj-866bd0af6eb94b89ba771bba630fed732020-11-25T01:35:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011010e013964210.1371/journal.pone.0139642Assessing the Power of Exome Chips.Christian Magnus PageSergio E BaranziniBjørn-Helge MevikSteffan Daniel BosHanne F HarboBettina Kulle AndreassenGenotyping chips for rare and low-frequent variants have recently gained popularity with the introduction of exome chips, but the utility of these chips remains unclear. These chips were designed using exome sequencing data from mainly American-European individuals, enriched for a narrow set of common diseases. In addition, it is well-known that the statistical power of detecting associations with rare and low-frequent variants is much lower compared to studies exclusively involving common variants. We developed a simulation program adaptable to any exome chip design to empirically evaluate the power of the exome chips. We implemented the main properties of the Illumina HumanExome BeadChip array. The simulated data sets were used to assess the power of exome chip based studies for varying effect sizes and causal variant scenarios. We applied two widely-used statistical approaches for rare and low-frequency variants, which collapse the variants into genetic regions or genes. Under optimal conditions, we found that a sample size between 20,000 to 30,000 individuals were needed in order to detect modest effect sizes (0.5% < PAR > 1%) with 80% power. For small effect sizes (PAR <0.5%), 60,000-100,000 individuals were needed in the presence of non-causal variants. In conclusion, we found that at least tens of thousands of individuals are necessary to detect modest effects under optimal conditions. In addition, when using rare variant chips on cohorts or diseases they were not originally designed for, the identification of associated variants or genes will be even more challenging.http://europepmc.org/articles/PMC4593624?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Christian Magnus Page
Sergio E Baranzini
Bjørn-Helge Mevik
Steffan Daniel Bos
Hanne F Harbo
Bettina Kulle Andreassen
spellingShingle Christian Magnus Page
Sergio E Baranzini
Bjørn-Helge Mevik
Steffan Daniel Bos
Hanne F Harbo
Bettina Kulle Andreassen
Assessing the Power of Exome Chips.
PLoS ONE
author_facet Christian Magnus Page
Sergio E Baranzini
Bjørn-Helge Mevik
Steffan Daniel Bos
Hanne F Harbo
Bettina Kulle Andreassen
author_sort Christian Magnus Page
title Assessing the Power of Exome Chips.
title_short Assessing the Power of Exome Chips.
title_full Assessing the Power of Exome Chips.
title_fullStr Assessing the Power of Exome Chips.
title_full_unstemmed Assessing the Power of Exome Chips.
title_sort assessing the power of exome chips.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Genotyping chips for rare and low-frequent variants have recently gained popularity with the introduction of exome chips, but the utility of these chips remains unclear. These chips were designed using exome sequencing data from mainly American-European individuals, enriched for a narrow set of common diseases. In addition, it is well-known that the statistical power of detecting associations with rare and low-frequent variants is much lower compared to studies exclusively involving common variants. We developed a simulation program adaptable to any exome chip design to empirically evaluate the power of the exome chips. We implemented the main properties of the Illumina HumanExome BeadChip array. The simulated data sets were used to assess the power of exome chip based studies for varying effect sizes and causal variant scenarios. We applied two widely-used statistical approaches for rare and low-frequency variants, which collapse the variants into genetic regions or genes. Under optimal conditions, we found that a sample size between 20,000 to 30,000 individuals were needed in order to detect modest effect sizes (0.5% < PAR > 1%) with 80% power. For small effect sizes (PAR <0.5%), 60,000-100,000 individuals were needed in the presence of non-causal variants. In conclusion, we found that at least tens of thousands of individuals are necessary to detect modest effects under optimal conditions. In addition, when using rare variant chips on cohorts or diseases they were not originally designed for, the identification of associated variants or genes will be even more challenging.
url http://europepmc.org/articles/PMC4593624?pdf=render
work_keys_str_mv AT christianmagnuspage assessingthepowerofexomechips
AT sergioebaranzini assessingthepowerofexomechips
AT bjørnhelgemevik assessingthepowerofexomechips
AT steffandanielbos assessingthepowerofexomechips
AT hannefharbo assessingthepowerofexomechips
AT bettinakulleandreassen assessingthepowerofexomechips
_version_ 1725067498132340736